NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

NCT07100080

RecruitingPhase 2, Phase 3

Sponsor: Bristol-Myers Squibb

Conditions: Non-Small Cell Lung Cancer

Interventions: Iza-bren, Carboplatin, Cisplatin, Pemetrexed

Countries: United States, Argentina, Belgium, Canada, Chile, China, Colombia, France

A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Non-squamous NSCLC, not amenable to treatment in curative intent.
* Documented evidence of EGFR mutation (exon 19 deletion, L858R mutation).
* Progressive disease on a 3rd-generation (such as osimertinib, furmonertinib, lazertinib,...) EGFR-TKI-based mono- or combination therapy regimen as the most recent line of therapy in an adjuvant, locally advanced, or metastatic treatment setting.
* Eligible to receive a platinum-based doublet chemotherapy regimen (either cisplatin or carboplatin in combination with pemetrexed).

Exclusion criteria:

* Inadequate organ function and/or bone marrow reserve.
* Leptomeningeal metastases or spinal cord compression.
* Poorly controlled systemic medical conditions.
* Other protocol-defined inclusion/exclusion criteria apply.

Locations (186)

Irvine, California, United States
Orange, California, United States
Edwards, Colorado, United States
Gainesville, Florida, United States
Pembroke Pines, Florida, United States
Atlanta, Georgia, United States
Columbus, Georgia, United States
Chicago, Illinois, United States
Boston, Massachusetts, United States
St Louis, Missouri, United States
Reno, Nevada, United States
Mineola, New York, United States
New York, New York, United States
New York, New York, United States
Rochester, New York, United States
Cleveland, Ohio, United States
Columbus, Ohio, United States
Portland, Oregon, United States
Portland, Oregon, United States
Portland, Oregon, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Chattanooga, Tennessee, United States
Nashville, Tennessee, United States
Houston, Texas, United States
San Antonio, Texas, United States
Charlottesville, Virginia, United States
Richmond, Virginia, United States
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
ABB, Buenos Aires F.D., Argentina
+ 156 more on CT.gov